A Novel Individualized Connectome-guided Approach for Precision Intermittent Theta Burst Stimulation for Depression
A Novel Individualized Connectome-guided Approach for Precision Intermittent Theta Burst Stimulation for Depression: a Double Blind, Randomized Controlled Trial
Institute of Mental Health, Singapore
70 participants
Jul 1, 2024
INTERVENTIONAL
Conditions
Summary
The Investigators propose to carry out a randomized, double-blind trial to compare the clinical efficacy of an individualized connectome-guided accelerated iTBS vs an anatomically-guided (Beam F3) accelerated iTBS. The study team will recruit both inpatients and outpatients who had been referred for TMS for the treatment of depression.
Eligibility
Inclusion Criteria5
- Age ≥ 21 years.
- DSM-5 diagnosis of current Major Depressive Episode.
- Montgomery-Asberg Depression Rating Scale score of 20 or more.
- Inadequate response to an adequate trial (4 weeks) of at least one antidepressant medication.
- Able to give informed consent.
Exclusion Criteria7
- DSM-5 psychotic disorder
- Drug or alcohol abuse or dependence (preceding 3 months).
- Rapid clinical response required, e.g., high suicide risk.
- Significant neurological disorder, which may pose increased risks with TMS, e.g., epilepsy.
- Metal in the cranium, skull defects, pacemaker, cochlear implant, medication pump or other electronic device.
- Pregnancy.
- Unsuitable for MRI.
Interventions
Magpro X100, Axilium Cobot, Localite camera
Magpro X100, Axilium Cobot, Localite camera
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06385223